A Randomized, Controlled, Partially Masked, Phase 3b Study to Assess the Injection Burden, Efficacy, Safety, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec (ABBV-RGX-314) in a Real-World Context in Subjects With Neovascular Age-Related Macular Degeneration (nAMD)
A Randomized, Controlled, Partially Masked, Phase 3b Study to Assess the Injection Burden, Efficacy, Safety, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec (ABBV-RGX-314) in a Real-World Context in Subjects With Neovascular Age-Related Macular Degeneration (nAMD)
Neovascular age-related macular degeneration (nAMD), also known as "wet" AMD, is the abnormal growth of new blood vessels in the light-sensitive tissue at the back of the eye called the retina. The purpose of this study is to assess how safe and effective Surabgene Lomparvovec is in treating participants with Neovascular age-related macular degeneration (nAMD).
Surabgene Lomparvovec (ABBV-RGX-314) is an investigational gene therapy being developed for the treatment of neovascular age-related macular degeneration (nAMD). Participants will be placed into 1 of 3 groups, called treatment arms. Each group receives different treatment. Adult participants aged 50 and older years with a diagnosis of previously treated nAMD will be enrolled. Around 561 participants will be enrolled in the study at approximately 150 sites worldwide.
Participants in groups 1 and 2 will receive a single subretinal dose of ABBV-RGX-314. Participants in group 3 will receive Ranibizumab as needed throughout the study. Ranibizumab will be given as an intravitreal injection (injection into the jelly-like tissue that fills the eyeball injection), and ABBV-RGX-314 will be given as a subretinal (between the retina and the back of the eye) injection. The Assessment Period begins after randomization (1:1:1) to one of the ABBV-RGX-314 treatment groups or control at Week -2 and lasts up to 5 years.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular monthly visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Inclusion Criteria:
Pseudophakic (at least 12 weeks post cataract surgery at Screening Visit 1 [Week -6]) in the study eye.
Must have a diagnosis of choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) in the study eye
--CNV lesion characteristics as assessed by the central reading center: lesion size needs to be less than 10-disc areas (typical disc area = 2.54 mm^2)
Must have received at least 2 intravitreal anti-vascular endothelial growth factor (VEGF) injections in the past 6 months in the study eye prior to Screening Visit 1 (Week -6) and have been responsive (determined by investigator)
Exclusion Criteria:
abbvieclinicaltrials@abbvie.com844-663-3742
Huntington Beach, California 92647, United States
Mountain View, California 94040-4119, United States
Redlands, California 92374, United States
Riverside, California 92505, United States
Sacramento, California 95841, United States
San Francisco, California 94143-2510, United States
Colorado Springs, Colorado 80909, United States
Fort Myers, Florida 33917, United States
Jacksonville, Florida 32216, United States
Winter Haven, Florida 33880, United States
Edina, Minnesota 55435, United States
Columbus, Ohio 43212, United States
Bluffton, South Carolina 29910, United States
Charleston, South Carolina 29414, United States
Ladson, South Carolina 29456, United States
Mt. Pleasant, South Carolina 29464, United States
Burgas, 8005, Bulgaria
Sofia, 1784, Bulgaria
Grad Zagreb, City of Zagreb 10000, Croatia
Prague, Praha 6 169 02, Czechia
Nice, Alpes-Maritimes 06001, France
Nantes, Pays de la Loire Region 44000, France
Créteil, Val-de-Marne 94010, France
Paris, Île-de-France Region 75571, France
Freiburg im Breisgau, Baden-Wurttemberg 79106, Germany
Göttingen, Lower Saxony 37075, Germany
Ludwigshafen am Rhein, Rhineland-Palatinate 67063, Germany
Lübeck, Schleswig-Holstein 23538, Germany
Berlin, 12203, Germany
Holon, Central District 5822012, Israel
Cona, Ferrara 44124, Italy
Rome, Roma 00168, Italy
Reggio Emilia, 42122, Italy
Donostia / San Sebastian, Guipuzcoa 20014, Spain
Majadahonda, Madrid 28222, Spain
Asturias, Principality of Asturias 33012, Spain
Barcelona, 08028, Spain
Gloucester, Gloucestershire GL1 3NN, United Kingdom
Liverpool, Merseyside L9 7AL, United Kingdom
+30210 5831336
0191 5699039